Ziprasidone in treatment of resistant obsessive-compulsive disorder in a female adolescent

While serotonin reuptake inhibitors [SSRIs] and behavioral therapy are the first-line agents in treatment of obsessive-compulsive disorder [OCD], 40-60% of patients with the disorder do not respond to therapy. So other neurotransmitters may play a role in OCD. In this regard, there has been particular interest in the dopaminergic system, with various antipsychotic drugs having been used as adjunctive therapy for refractory OCD. This study describes the efficacy of ziprasidone as adjuncts for treatment-resistant OCD in a young female adolescent